182 related articles for article (PubMed ID: 22151893)
1. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
Gonçalves A; Leal E; Paiva A; Teixeira Lemos E; Teixeira F; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Diabetes Obes Metab; 2012 May; 14(5):454-63. PubMed ID: 22151893
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
Marques C; Mega C; Gonçalves A; Rodrigues-Santos P; Teixeira-Lemos E; Teixeira F; Fontes-Ribeiro C; Reis F; Fernandes R
Mediators Inflamm; 2014; 2014():538737. PubMed ID: 24817793
[TBL] [Abstract][Full Text] [Related]
4. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
Ferreira L; Teixeira-de-Lemos E; Pinto F; Parada B; Mega C; Vala H; Pinto R; Garrido P; Sereno J; Fernandes R; Santos P; Velada I; Melo A; Nunes S; Teixeira F; Reis F
Mediators Inflamm; 2010; 2010():592760. PubMed ID: 20652060
[TBL] [Abstract][Full Text] [Related]
5. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Takai S; Sakonjo H; Jin D
J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
[TBL] [Abstract][Full Text] [Related]
6. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F
Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
[TBL] [Abstract][Full Text] [Related]
8. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
9. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Jackson EK; Mi Z; Tofovic SP; Gillespie DG
Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Reimer RA; Grover GJ; Koetzner L; Gahler RJ; Juneja P; Lyon MR; Wood S
J Nutr; 2012 Oct; 142(10):1812-20. PubMed ID: 22915295
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
Huang CY; Shih CM; Tsao NW; Lin YW; Huang PH; Wu SC; Lee AW; Kao YT; Chang NC; Nakagami H; Morishita R; Ou KL; Hou WC; Lin CY; Shyu KG; Lin FY
Br J Pharmacol; 2012 Dec; 167(7):1506-19. PubMed ID: 22788747
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
Jäckle A; Ziemssen F; Kuhn EM; Kampmeier J; Lang GK; Lang GE; Deissler H; Deissler HL
J Diabetes Res; 2020; 2020():2450781. PubMed ID: 32566677
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney.
Joo KW; Kim S; Ahn SY; Chin HJ; Chae DW; Lee J; Han JS; Na KY
BMC Nephrol; 2013 Apr; 14():98. PubMed ID: 23621921
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
Vittone F; Liberman A; Vasic D; Ostertag R; Esser M; Walcher D; Ludwig A; Marx N; Burgmaier M
Diabetologia; 2012 Aug; 55(8):2267-75. PubMed ID: 22648661
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin exerts an antinflammatory action.
Makdissi A; Ghanim H; Vora M; Green K; Abuaysheh S; Chaudhuri A; Dhindsa S; Dandona P
J Clin Endocrinol Metab; 2012 Sep; 97(9):3333-41. PubMed ID: 22745245
[TBL] [Abstract][Full Text] [Related]
16. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
17. The effects of DPP-IV inhibition in NOD mice with overt diabetes.
Vargová L; Zacharovová K; Dovolilová E; Vojtová L; Cimburek Z; Saudek F
Folia Biol (Praha); 2013; 59(3):116-22. PubMed ID: 23890479
[TBL] [Abstract][Full Text] [Related]
18. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Zerilli T; Pyon EY
Clin Ther; 2007 Dec; 29(12):2614-34. PubMed ID: 18201579
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of clusterin on blood-retinal barrier breakdown in diabetic retinopathy.
Kim JH; Kim JH; Yu YS; Min BH; Kim KW
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1659-65. PubMed ID: 19875648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
